Search results for "OTHER"

Adjuvant Intravesical Chemotherapy in Patients with Primary T1 G3 Transitional Cell Carcinoma of the Bladder

1993

The Authors present their experience with TUR plus adjuvant intravesical chemotherapy in 50 patients affected by primary T1 G3 bladder tumours without previous or concomitant carcinoma in situ. At a mean follow-up of 36 months, 84% of the patients are alive and tumour-free. Cystectomy was performed in three patients due to locally invasive disease. Five patients (10%) died of bladder cancer.

Cardiac arrhythmia induced by hypothermia in a cardiac model in vitro

2013

The neurological damage after cardiac arrest (CA) constitutes a big challenge of hospital discharge since years. The therapeutic hypothermia therapy (34°C-32°C) has shown its benefit to reduce cerebral oxygen demand and improve neurological outcomes after the cardiac arrest. Despite the fact that induced hypothermia after CA has been shown to increase the hospital survival rate, it can have many adverse effects, among which the cardiac arrhythmia generation represents an important part (up to 34%, according different clinical studies). Compared to studies in vivo, cardiac culture in vitro provides a better spatial resolution at cellular level, which could bring some insights of the mechanis…

Topical 5'-methylthioadenosine in the treatment of symptomatic chronic venous insufficiency, haemorrhoids and superficial phlebitis. A double-blind p…

1992

500 patients entered a randomised double-blind placebo-controlled trial designed to evaluate the efficacy and tolerability of topical 5′-methylthioadenosine (MTA) 0.5% in relieving the major signs and symptoms related to chronic venous insufficiency, superficial phlebitis and first and second degree haemorrhoids.

Why do antidepressant therapies have such a poor success rate?

2016

Major depression is one of the leading global diseases [1,2]. Treatment is required, because untreated patients suffer not only from impaired emotion [3,4], but also from cognitive [4–6] and somati...

Baseline patient characteristics of the German multicentric prospective real-world NAFLD cohort: The Fatty Liver Assessment in Germany (FLAG) study

2019

Unintentional hypothermia in the surgical patient. Old solutions to an old problem, or new solutions to an old problem?

2018

P-34 The randomized, double-blind, placebo-controlled phase 3 trial KEYNOTE-975: Pembrolizumab vs placebo in patients with esophageal carcinoma recei…

2020

Chirurgische Therapie von Lebermetastasen kolorektaler Karzinome

2003

Resection is the only curative treatment of colorectal liver metastases proofed by a long-term follow-up. The operation is indicated if the metastases are completely removable with sufficient liver parenchyma remaining after resection and if the patient is fit for surgery. The resection is not indicated in cases with non resectable extrahepatic tumours and lymph node metastases distal the hepatoduodenal ligament. The postoperative mortality amounts to about 5 % and the 5-year-survival-rates range between 20 and 40 % depending on the selection of patients. Aims of new concepts of operative therapy are the improvement of resectability by preoperative portal vein embolization, the resection co…

Azacitidine-Containing Induction Regimens Followed by Azacitidine Maintenance Therapy in High Risk Acute Myeloid Leukemia: First Results of the Rando…

2012

Abstract Abstract 412 Background: A large proportion of patients are currently not eligible for genotype-adapted strategies in acute myeloid leukemia (AML), in particular those lacking specific genetic aberrations such as PML-RARA, CBFB-MYH11, RUNX1-RUNX1T1, NPM1 or activating FLT3 mutations. This subgroup of patients accounts for about one-third of all AML patients and mainly includes the large group of AML with myelodysplasia-related changes, AML with recurrent cytogenetic abnormalities [inv(3) or t(3;3), t(9;11), t(v;11q23)] and cytogenetically normal AML (CN-AML) with wild-type NPM1 and FLT3. Prognosis in this subgroup of patients is generally poor. Azacitidine has been shown to be acti…

Prognostic Parameters For Remission Of and Survival In Acquired Hemophilia A: Results Of The GTH-AH 01/2010 Multicenter Study

2013

Abstract Acquired hemophilia A (AHA) is a rare autoimmune disorder caused by neutralizing autoantibodies against coagulation factor VIII (FVIII:C). Immunosuppressive treatment may result in remission of disease over a period of days to months. Until remission, patients are at high risk of bleeding and complications from immunosuppression. Prognostic parameters to predict remission and the time needed to achieve remission could be helpful to guide treatment intensity, but have not been established so far. GTH-AH01/2010 was a prospective multicenter cohort study using a standardized immunosuppressive treatment protocol. The primary study endpoint was time to achieve partial remission (PR, def…